Literature DB >> 33067992

Contribution of Components of Metabolic Syndrome to Cognitive Performance in Middle-Aged Adults.

Karamfil M Bahchevanov1, Angel M Dzhambov2, Kostadin A Chompalov1, Radka I Massaldjieva3, Penka A Atanassova1, Mitko D Mitkov4.   

Abstract

INTRODUCTION: Metabolic syndrome (MetS) has been associated with impaired cognition in different cognitive domains. This study investigated the association between MetS and cognitive functioning in middle-aged Bulgarians across different definitions of MetS severity.
MATERIAL AND METHODS: Our cross-sectional sample included 112 participants (67 free of MetS and 45 with MetS) with a mean age of 50.04 ± 3.31 years. The following MetS variables were considered-presence of MetS, continuously measured MetS components, dichotomized MetS components, number of MetS components present, and Metabolic Syndrome Severity Score (MSSS). Participants' cognitive performance was assessed using the Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery (CERAD-NB). We employed multivariate regression models to investigate the associations between different measures of MetS severity and CERAD-NB total and subtest scores.
RESULTS: Bivariate analyses showed that the CERAD-NB total score was significantly higher in women, participants with a university degree, those with normal blood pressure, normal waist circumference, and low triglyceride levels, compared with their counterparts. MetS participants had lower CERAD-NB total score (78.87 ± 6.89 vs. 84.97 ± 7.84) and specifically performed poorer on the subtest Word List Recall (7.16 ± 1.52 vs. 7.99 ± 1.52). These findings persisted after controlling for age, gender, and education. Next, generalized linear regression indicated that the CERAD-NB total score was lower in participants with MetS (β = -4.86; 95% confidence interval [CI]: -7.60, -2.11), those with more MetS components (β = -8.31; 95% CI: -14.13, -2.50 for fours vs. 0 components) and with an increase in MSSS (β = -3.19; 95% CI: -4.67, -1.71). Hypertension independently contributed to lower CERAD-NB total score (β = -4.00; 95% CI: -6.81, -1.19).
CONCLUSIONS: Across several definitions, MetS was associated with lower cognitive functioning, and MetS severity appeared to be a better predictor than most MetS components. Recognizing and reducing severity of MetS components might be helpful in supporting cognitive functioning. Further longitudinal research is needed to shed more light on the relationship between MetS and cognitive functioning across the life span.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; Cardiovascular disease; Cerebrovascular disease/accident and stroke; Mild cognitive impairment

Year:  2021        PMID: 33067992     DOI: 10.1093/arclin/acaa081

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  4 in total

Review 1.  Natural Aporphine Alkaloids with Potential to Impact Metabolic Syndrome.

Authors:  Fei-Xuan Wang; Nan Zhu; Fan Zhou; Dong-Xiang Lin
Journal:  Molecules       Date:  2021-10-10       Impact factor: 4.411

Review 2.  Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.

Authors:  Kah Kheng Goh; Cynthia Yi-An Chen; Tzu-Hua Wu; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

3.  Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis.

Authors:  Dominic Kaddu-Mulindwa; Matthias Heit; Gudrun Wagenpfeil; Moritz Bewarder; Klaus Fassbender; Stefanie Behnke; Umut Yilmaz; Mathias Fousse
Journal:  Front Neurol       Date:  2022-08-23       Impact factor: 4.086

4.  Effect of a Community Gerontology Program on the Control of Metabolic Syndrome in Mexican Older Adults.

Authors:  Víctor Manuel Mendoza-Núñez; Gabriela Pulido-Castillo; Elsa Correa-Muñoz; Juana Rosado-Pérez
Journal:  Healthcare (Basel)       Date:  2022-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.